Jefferies Group Analysts Decrease Earnings Estimates for Zoetis Inc (ZTS)
Zoetis Inc (NYSE:ZTS) – Investment analysts at Jefferies Group reduced their FY2017 earnings per share (EPS) estimates for shares of Zoetis in a note issued to investors on Tuesday. Jefferies Group analyst J. Holford now expects that the company will post earnings of $2.38 per share for the year, down from their previous forecast of $2.39. Jefferies Group has a “Buy” rating and a $89.00 price target on the stock. Jefferies Group also issued estimates for Zoetis’ FY2019 earnings at $3.59 EPS, FY2020 earnings at $4.06 EPS and FY2021 earnings at $4.47 EPS.
Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the business posted $0.52 earnings per share.
Shares of Zoetis (NYSE ZTS) opened at $76.77 on Thursday. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. The firm has a market cap of $37,410.00, a price-to-earnings ratio of 40.41, a price-to-earnings-growth ratio of 1.90 and a beta of 1.06. Zoetis has a twelve month low of $52.00 and a twelve month high of $77.03.
A number of institutional investors have recently added to or reduced their stakes in ZTS. Janus Henderson Group PLC grew its position in Zoetis by 7,717.4% in the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock valued at $362,372,000 after purchasing an additional 5,734,776 shares in the last quarter. Vanguard Group Inc. grew its position in Zoetis by 2.8% in the second quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock valued at $2,099,379,000 after purchasing an additional 910,265 shares in the last quarter. Parametric Portfolio Associates LLC grew its position in Zoetis by 68.1% in the second quarter. Parametric Portfolio Associates LLC now owns 1,683,496 shares of the company’s stock valued at $105,016,000 after purchasing an additional 681,877 shares in the last quarter. Renaissance Technologies LLC grew its position in Zoetis by 51.2% in the second quarter. Renaissance Technologies LLC now owns 1,711,100 shares of the company’s stock valued at $106,738,000 after purchasing an additional 579,400 shares in the last quarter. Finally, Milestone Resources Group Ltd bought a new position in Zoetis in the fourth quarter valued at $40,294,000. 93.14% of the stock is owned by institutional investors and hedge funds.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be given a $0.126 dividend. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a yield of 0.66%. This is an increase from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio (DPR) is 22.11%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.